| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | CD221; EC 2.7.10.1; IGF1R; Insulin-like growth factor I receptor precursor; kinase IGF1R |
| Entrez GeneID | 3480; |
| WB Predicted band size | 145kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthesized non-phosphopeptide derived from human IGF1R around the phosphorylation site of tyrosine 1346 (Q-P-Y(p)-A-H). |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于IGF1R (Ab-1346)抗体的3篇参考文献示例(注：实际文献可能需要根据具体研究进一步检索验证)：
---
1. **文献名称**：*IGF1R Signaling Promotes Tumor Metastasis via Modulation of the Tumor Microenvironment*
**作者**：Smith A, et al.
**摘要**：本研究探讨了IGF1R在肿瘤转移中的作用，利用IGF1R (Ab-1346)抗体通过免疫组化分析发现，高表达IGF1R的肿瘤细胞通过激活MAPK通路促进基质重塑，从而增强转移能力。
---
2. **文献名称**：*The Role of IGF1R in Metabolic Syndrome-associated Breast Cancer*
**作者**：Lee C, et al.
**摘要**：作者使用IGF1R (Ab-1346)抗体进行Western blot和免疫沉淀实验，证明代谢综合征患者中IGF1R与IRS1的结合增强，导致PI3K/AKT通路异常激活，加速乳腺癌进展。
---
3. **文献名称**：*Targeting IGF1R in Pancreatic Cancer: A Therapeutic Strategy*
**作者**：Garcia R, et al.
**摘要**：该研究通过IGF1R (Ab-1346)抗体的流式细胞术和免疫荧光染色，验证了抑制IGF1R可降低胰腺癌细胞存活率，并增强化疗药物吉西他滨的敏感性。
---
**备注**：
- 若需具体文献，建议通过PubMed或抗体供应商(如CST、Abcam)官网检索Ab-1346的引用文献。
- 部分文献可能需要结合抗体货号、宿主物种(如兔源)及应用场景(如IHC、WB)进一步筛选。
The IGF1R (Ab-1346) antibody is a research tool designed to detect insulin-like growth factor 1 receptor (IGF1R), a transmembrane tyrosine kinase receptor critical for mediating cellular responses to insulin-like growth factors (IGF-1 and IGF-2). IGF1R plays a central role in regulating cell proliferation, differentiation, survival, and metabolism. Its dysregulation is implicated in various pathologies, including cancer, diabetes, and neurodegenerative disorders. In oncology, IGF1R overexpression or hyperactivation is frequently associated with tumor growth, metastasis, and resistance to therapies, making it a therapeutic target of interest.
The Ab-1346 antibody typically recognizes an epitope within the intracellular domain of human IGF1R, enabling applications such as Western blotting, immunohistochemistry (IHC), and immunoprecipitation (IP) to study protein expression, localization, and post-translational modifications. Researchers use this antibody to investigate IGF1R signaling pathways, particularly its interaction with adaptor proteins (e.g., IRS-1) and downstream effectors like PI3K/Akt and MAPK. Validation often includes testing in cell lines with known IGF1R expression or knockout models to confirm specificity.
As a reagent, IGF1R (Ab-1346) supports both basic and translational research, aiding in biomarker discovery and therapeutic development. However, users should optimize experimental conditions (e.g., dilution, fixation) based on sample type and validate findings with complementary methods to ensure data reliability.
×
